NICE has announced that the immunotherapy nivolumab will now be made available on the Cancer Drugs Fund for treating locally advanced or metastatic squamous and non-squamous non-small-cell lung cancers after prior chemotherapy.
Browsing: Disease Area > Lung
Listen to this podcast to discover more about CheckMate-153 study, data from which was presented at this years 2017 ESMO Congress (8–12th September, Madrid, Spain).
Recent research demonstrates that the ratio of abdominal fat to peripheral fat is a significant independent predictor of cancer.
A recent clinical trial presents new data indicating durvalumab improves progression-free survival in patients with stage III non-small-cell lung cancer (NSCLC).
A study has indicated that patients with advanced inoperable stage 3 lung cancer can benefit from an improved rate of survival when undergoing concurrent chemotherapy and proton therapy.
A web-based tool that allows patients to report their symptoms to their clinicians in real time has been shown to increase survival rates in metastatic cancer patients.
Available to view on demand
Live event: Wednesday 14th June 2017 at 07:00 [PST] 10:00 [EST] 15:00 [GMT]
Learn about a study that was accomplished as a means to explore the hypothesis that circulating concentrations of decoy receptors and/or ligands, as well as disease-specific ligand degradation all regulate RTK signaling in vivo.
Phase I data indicate that nivolumab significantly increases long-term survival in previously treated, advanced non-small-cell lung cancer.
In this case report the authors present systematic therapy as a multimodality tool in the management of patients with oligometastatic disease.
Prospective clinical trial results demonstrate that a biomarker blood test could detect lung cancer recurrence on average 6 months earlier than CT scans.